AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04047511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group general fitness training
Description: A single session of general fitness training will be composed of low-intensity, general-fitness exercises. Most of the exercises will be carried out in a sitting position and standing positon. The session will contain aerobic (general warm-up), musculo-articular (strengthening muscles and joints range of motion) and stabilizing exercises (improve spatio-visual coordination). Perception of effort will be monitored using the Borg 6-20 rating the perceived exertion. Conducted by a physiotherapist in group form.
Study NCT04047511 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Psychoeducation
Description: A single sesstion will contain mini-lectures about mental well-being and psychohygiene, conduced by a psychotherapist in group form.
Study NCT01441817 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Internal fixation
Description: Internal fixation of the medial malleolus following open reduction and internal fixation of the lateral and, if required, posterior malleolus.
Study NCT03154372 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Expert supervised practice with validated metrics
Study NCT03154372 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: self guided practice with validated metrics
Study NCT03018002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iSTAR
Description: Each component of the iSTAR intervention targets a specific point along the HIV continuum: confidential, onsite integrated laboratory tests during baby showers targets HIV diagnosis (b) church-based Health Advisors (CHAs) trained in motivational interviewing and quality improvement skills as promotoras target linkage, engagement and adherence by providing counseling and other support to HIV-infected women and children (c) integrated network of community and clinic case management targets reduction in loss to follow-up.~CHAs will support participants during the study period by being available to accompany them to clinic visits, review laboratory results and medications after clinic visits. They will be available to speak with them at intervals to see how they are doing either by phone or through home visits as they prefer. At each follow-up study visit, the trained CHA will review and collect data on participants' clinic visits, treatment, and laboratory results.
Study NCT04627519 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rhea Health Tone®
Description: Rhea Health Tone® 2 ml twice daily after the meal (every 12 hours)
Study NCT01216163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel Ibuprofen
Description: Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
Study NCT01216163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Single-dose of acetaminophen (1000mg)
Study NCT01216163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single-dose of placebo
Study NCT00152009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503 (Guanfacine hydrochloride) (2 mg)
Study NCT00152009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503 (3 mg)
Study NCT00152009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503 (4 mg)
Study NCT00152009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03597035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: The study participants will receive concomitant treatment with Veltassa 8.4 grams per day and Spironolactone 25 mg per day or maximum tolerated dose. If dictated by the potassium level, Veltassa can be increased to 16.8 grams per day.
Study NCT02786264 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine with propofol
Description: A dexmedetomidine- dominant anesthetic will be defined as an anesthetic that included a continuous infusion of dexmedetomidine within 15 minutes of anesthesia start. This group was subsequently modified in light of retrospective data collection to specify a group receiving dexmedetomidine in combination with propofol.
Study NCT02786264 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: A propofol-dominant anesthetic will be defined as an anesthetic that included a continuous infusion of propofol within 15 minutes of anesthesia start. This definition was subsequently modified to include patients who received propofol infusion but not dexmedetomidine.
Study NCT00989586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: milatuzumab
Description: Patient will receive milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive milatuzumab on day 2. Starting in week 2, milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
Study NCT00989586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: veltuzumab
Description: Patient will receive veltuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
Study NCT00989586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Correlative/Special Studies
Description: To correlate Fcγ receptor polymorphisms with response to treatment with the combination of veltuzumab and milatuzumab. Whole blood will be collected pre-treatment on day 1.
Study NCT00989586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantitative T-, B-, and NK cell subsets
Description: Quantitative T-, B-, and NK- cell subsets will be assessed using flow cytometry to quantify the percentage and absolute number of cells expressing CD4, CD8, CD56, CD16, CD19, and CD20 pre-treatment on day 1, after induction (week 5, day 1), and prior to the start of therapy on day 1 week 12, day 1 week 36, and then every 4 months for one year.
Study NCT00989586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics
Description: To assess the pharmacokinetics of veltuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 1 of weeks 1, 2, 4, 12 and 36. One additional sample will be collected each of weeks 5 through 10 (sample may be collected any day during each of these weeks).
Study NCT00989586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics
Description: To assess the pharmacokinetics of milatuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 2 of week 1 and day 1 of weeks 2, 4, 12 and 36. Additional samples will be collected days 3 through 6 of week 1.
Study NCT00989586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human Anti-Human Antibodies
Description: To monitor for the development of human anti-veltuzumab antibodies and human anti-milatuzumab antibodies (HAHA) in patients receiving treatment with veltuzumab and milatuzumab. Patients will be monitored for the development of HAHA at the following timepoints: pre-treatment on day 1 of week 1, pre-treatment on day 1 of week 4, pre-treatment on day 1 of week 12, and pre-treatment on day 1 of week 36.
Study NCT00989586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: veltuzumab and milatuzumab
Description: Patient will receive veltuzumab and milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab on day 1 and milatuzumab on day 2. Starting in week 2, veltuxumab will be given on day 1 and milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
Study NCT02139657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RIG-C
Study NCT04618263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GATE-101
Description: GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist
Study NCT04618263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GATE-101
Description: GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist
Study NCT01222429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vegan diet
Description: Intervention group participants will follow a low-fat vegan diet and will receive instruction on this diet through the course of the study
Study NCT01222429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diet following ADA guidelines
Description: participants will be given instruction on the ADA guidelines for diabetes, and will follow an individualized plan based on these guidelines
Study NCT00993824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: colesevelam HCl
Description: 3.75 grams of colesevelam HCl (6 tablets)
Study NCT00993824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01749072 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gefitinib group
Description: Gefitinib 250mg once per day until the progression disease or intolerant side effects
Study NCT01749072 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vinorelbine, Ifosfamide, Mesna
Description: Vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m1 d1-d3 (Usually 2g d1-d3); Mesna 400mg 0,4,8 hours after Ifosfamide administration for uroprotection d1-d3;
Study NCT03148236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: 200mg/kg/day split into 4 doses infused every six hours over 30 minutes in 50ml D5W
Study NCT03148236 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50mL infused over 30 minutes
Study NCT01406002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban
Description: oral
Study NCT01406002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: oral
Study NCT01526590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity Contrast
Description: While the patient is still sedated from their EUS and before tissue sampling, the patient will receive a dose of Definity intravenously through their peripheral IV access after being agitated. The dose of Definity will be 10 microliters/kg given in one to two doses, and will not exceed 2cc.
Study NCT02230436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early drain removal
Description: Removing drain(s) on postoperative day 3
Study NCT02230436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late drain removal
Description: Removing drain(s) on postoperative day 4 or later
Study NCT01285284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: A previously defined list of songs will be administered by headphones to these patients.
Study NCT01285284 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No music
Description: No music will be administered by the headphones connected to the MP3 device.
Study NCT02192775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MV-NIS
Description: one dose in conjunction with a 4 day course intravenously
Study NCT01478074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg daily from day -7 until post-nadir ANC > 1000
Study NCT01478074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2 g/m2 daily from day -6 through -2
Study NCT01478074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 daily from day -6 through -2
Study NCT01478074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Natural Killer (NK) cells
Description: Infused once on day 0. Four cohorts of escalating doses receiving 0, 1, 10, or 20 x 10\^6 cells/Kg
Study NCT01478074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: 0.04 mg/kg IV thrice weekly for 8 doses beginning day +2
Study NCT01821417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microtextured dental implant treatment
Description: Microtextured dental implant treatment will include a surgically inserted device implanted into edentulous areas of the jaw where natural teeth have been lost and adequate bone exists.
Study NCT01821417 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant treatment
Description: Treatment with dental implants; implants with a machined collar will be surgically implanted into edentulous areas of the jaw where natural teeth have been lost and adequate bone exists.
Study NCT01535742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu Aura-i size 1.5
Description: Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
Study NCT01535742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: air-Q ILA size 1.5
Description: Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
Study NCT01535742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu Aura-i size 2
Description: Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
Study NCT01535742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: air-Q ILA size 2
Description: Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
Study NCT02869919 — intervention group
Intervention type: OTHER
Intervention: AKI
Description: Vitamin D levels
Study NCT00544960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-101 and docetaxel
Description: AT-101 30 mg bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
Study NCT00544960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo and docetaxel
Description: placebo 3 tabs bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
Study NCT04599101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nose Frida nasal suction device
Description: Caregivers will be given a Nose Frida device to remove the child's nasal secretions.
Study NCT04599101 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bulb syringe nasal suction device
Description: Caregivers will be given a bulb syringe device to remove the child's nasal secretions.
Study NCT00709748 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Empi Select TENS Device
Description: The Empi Select TENS device delivers therapeutic electrical currents at various frequencies (intensities) and periods of time for the treatment of pain.
Study NCT00709748 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
Study NCT02790723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sc-rAAV2.5IL-1Ra
Description: Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.
Study NCT03628963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concerto+
Description: a user-centered, multifunctional and personalized eHealth platform
Study NCT04103268 — intervention group
Intervention type: OTHER
Intervention: sepsis
Description: patients in the ICU with infection called sepsis
Study NCT05389891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemoglobinopathy Nursing Program
Description: Hemoglobinopathy Nursing Program is more informative for Groupe 1 than Group 2
Study NCT03946800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI1191
Description: Subjects will receive MEDI1191 (at least twice)
Study NCT03946800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Subject will receive durvalumab every 4 weeks
Study NCT06190691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally
Study NCT01181505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine
Study NCT03264963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart phone game play
Description: Voice controlled smart phone game play 15 minutes daily and recording sounds of sleep environment 2 night per week for 12 weeks
Study NCT03264963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Recording of sleep environment 2 nights per week for 12 weeks
Study NCT02507778 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CellCollectorTM (Gilupi, Germany) needle
Description: needle will be inserted before and after biopsy and will measure circulating tumor cells.
Study NCT02377037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metabolic cost and HR associated with distinct postural behaviors
Description: The order of the three conditions will be randomly assigned and all will be undertaken in laboratory settings. Before engaging in the experimental conditions participants will perform anthropometric and body composition assessments and also the resting EE evaluation. All evaluations will be performed at one time only, starting at 7:00 am in the morning after an overnight fast
Study NCT01081041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously
Study NCT01081041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously
Study NCT01081041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously
Study NCT01081041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Administered intravenously
Study NCT06082414 — intervention group
Intervention type: OTHER
Intervention: no interventions
Description: no interventions because of an observational study
Study NCT01737281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive outreach
Description: Proactive contact (mail and phone) offering smoking cessation medications and telephone counseling.
Study NCT01737281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual smoking cessation care from VA clinical staff.
Study NCT03369821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Beta Cell Loss and Immune Function
Description: Beta cell loss (measured by serum/urine C-peptide), islet-specific autoantibodies, T1D risk genes and autoreactive CD8 T cells.
Study NCT03369821 — intervention group
Intervention type: OTHER
Intervention: Immune Function with RNAseq
Description: Immune function (measuring autoantibodies, autoreactive CD8 T cells and RNAseq of immune genes).
Study NCT01960075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosphenytoin
Study NCT01960075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Study NCT01960075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic acid
Study NCT02820363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CERAMENT|G
Description: Surgical repair of tibia fracture, CERAMENT™\|G applied to bony voids.
Study NCT02820363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SOC treatment
Description: surgical repair of tibial fracture
Study NCT02820363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SOC treatment
Description: surgical repair of tibial fracture
Study NCT05851599 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SKF7® Labisia pumila standardized extract
Description: Botanical extract of Labisia pumila (Kacip Fatimah)
Study NCT05851599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SKF7® Labisia pumila standardized extract
Description: Botanical extract of Labisia pumila (Kacip Fatimah)
Study NCT02571790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation optimized virtual reality
Study NCT02571790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classical relaxation (without Virtual Reality)
Study NCT01618890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic venous pressure gradient measurement
Description: Perform baseline HVPG measurement, then start propranolol 20 mg orally twice daily (BID), increase the dose stepwise to maximum tolerated dose. After 4 weeks a second HVPG is performed.~In hemodynamic nonresponders from the study arm, repeated endoscopic band ligation is performed in daycare setting with intervals of 2-4 weeks.~In hemodynamic responders (HVPG second measurement\< 12 mmHg or >20% reduction in HVPG compared to baseline) beta-blockers are continued until end of follow-up.